Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

necrotizing soft tissue infection (NSTI) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

necrotizing soft tissue infection

MONDO:0018602

Also known as:NSTI

Find Clinical TrialsTrials

Overview

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials6 registered · 3 recruiting

Diagnosis

Biomarker and diagnostic research for necrotizing soft tissue infection has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for necrotizing soft tissue infection. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for necrotizing soft tissue infection, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for necrotizing soft tissue infection. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

6 clinical trials registered, 3 recruiting. Interventions under study include other interventions, medical devices, and drug therapy. Pipeline includes 1 PHASE4, 2 NA. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07107555](https://clinicaltrials.gov/study/NCT07107555)

Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 1:44 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:440368

GARD

Genetic and Rare Diseases Info Center

GARD:21839

Questions for Your Care Team

→Are any of the 6 active clinical trials a good fit for my situation?
→What is the current development status of reltecimod, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	104	58%
Research summaries	27	15%
Disease patterns and progression	21	12%
Testing and diagnosis research	10	6%
Clinical study results	10	6%
Laboratory research	5	3%
Other research	2	1%

Kisho

necrotizing soft tissue infection

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Haemophilus influenzae type B (Hib) necrotizing soft tissue infection (NSTI) in a vaccinated 16-month-old Inuit boy: a case report.

Factors associated with in-hospital mortality in necrotising soft tissue infections. a multicentre retrospective cohort study.

necrotizing soft tissue infection

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Haemophilus influenzae type B (Hib) necrotizing soft tissue infection (NSTI) in a vaccinated 16-month-old Inuit boy: a case report.

Factors associated with in-hospital mortality in necrotising soft tissue infections. a multicentre retrospective cohort study.